Related Experiment Video
Updated: Apr 30, 2026
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
Published on: November 17, 2018
Getting personal with neoantigen-based therapeutic cancer vaccines
Nir Hacohen1, Edward F Fritsch, Todd A Carter
1Authors' Affiliations: Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract:
Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These "neoantigens" should provide highly specific targets for antitumor immunity. Although many challenges remain in producing and testing neoantigen-based vaccines customized for each patient, a neoantigen vaccine offers a promising new approach to induce highly focused antitumor T cells aimed at eradicating cancer cells.
Insights
Therapeutic cancer vaccines have struggled to eliminate tumors. Neoantigen vaccines, targeting tumor-specific mutated proteins, offer a promising new strategy for highly focused antitumor T cell responses to eradicate cancer.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Therapeutic cancer vaccines have historically faced challenges in effectively limiting human tumor growth.
- Advances in genome sequencing enable the identification of novel tumor-specific targets.
Purpose of the Study:
- To explore the potential of neoantigens as targets for cancer vaccines.
- To investigate the development of personalized neoantigen vaccines for cancer treatment.
Main Methods:
- Utilizing advances in genome sequencing to identify tumor-specific mutated proteins (neoantigens).
- Developing customized vaccines based on identified neoantigens.
Main Results:
- Neoantigens represent a new class of highly specific targets for antitumor immunity.
- Neoantigen-based vaccines aim to induce focused T cell responses against cancer cells.
Conclusions:
- Neoantigen vaccines present a promising new approach for cancer immunotherapy.
- Despite remaining challenges, personalized neoantigen vaccines offer a potential strategy for eradicating cancer cells.
More Related Videos
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...